Yahoo Finance Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply
We issued an updated report on Mylan N.V. MYL on Mar 6, 2020.
Once a global leader in the generics business, Mylan was facing challenging business conditions in North America and pricing pressures. The company undertook a strategic review of its business last year and decided to merge with Upjohn, Pfizer's PFE off-patent branded and generic established medicines business (includes Lipitor, Celebrex and Viagra), to create a new global pharmaceutical company. Pfizer’s shareholders would own 57% of the combined entity, while Mylan’s shareholders would own the remaining 43%.
In November 2019, Mylan and Pfizer announced the name of the new entity to be Viatris. Subsequently, the companies have announced two future Viatris board members. The merger will be completed by mid-2020.
We view this merger as a positive since Viatris will have a diverse portfolio across many geographies and focus on key therapeutic areas.
The combined business (EpiPen, Lipitor, Celebrex and Viagra among others) will be one of the leading generic businesses in the world.
Mylan has been plagued with various problems, of late, like lawsuits and pricing pressure, among others. Hence, the merger with Upjohn will provide Mylan a chance to turn over a new leaf and focus more on emerging markets.
Moreover, Mylan’s biosimilar business is progressing well. The FDA approved Fulphila, a biosimilar of Neulasta, which has significant potential. A phase III study is underway for a biosimilar of Eylea, in collaboration with Momenta. Mylan recently launched Ogivri (trastuzumab-dkst), a biosimilar of Roche’s blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States. The biosimilar of Avastin is already under review in the United States.
Last week, Mylan reported fourth-quarter results, wherein earnings beat estimates but sales missed the same. Nevertheless, the company’s new products did well in the quarter and achieved the target of $1 billion from Wixela, the generic of GlaxoSmithKline’s GSK Advair Diskus; Fulphila; and several other products. Other products like Creon, Influvac, Dona, Amitiza and Glatiramer Acetate 40 mg generated double-digit growth. Yupelri, developed in collaboration with Theravance Biopharma, Inc TBPH, also boosted growth.
However, Mylan warned that its business might be negatively impacted by the outbreak of the coronavirus epidemic, given the global nature of the company’s supply-chain operations and businesses.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Mylan N.V. (MYL) : Free Stock Analysis Report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
